Similar articles

• [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2006 Nov 30;148(48):54-5. MMW Fortschr Med. 2006. PMID: 17615773 German. No abstract available.
• Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.

  Ballantyne CM. Ballantyne CM. Am J Cardiol. 2005 Nov 7;96(9A):14K-19K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.003. Epub 2005 Sep 12. Am J Cardiol. 2005. PMID: 16291009 Review.
• Critical appraisal of revised cholesterol guidelines for the very high-risk patient.

  Rosenson R, Lloyd-Jones D; Working group from the Adult Treatment Panel III of the National Cholesterol Educational Program. Rosenson R, et al. Expert Rev Cardiovasc Ther. 2005 Jan;3(1):173-8. doi: 10.1586/14779072.1.3.173. Expert Rev Cardiovasc Ther. 2005. PMID: 15739256 Review.
• Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.

  McKenney JM. McKenney JM. Am J Cardiol. 2005 Aug 22;96(4A):60E-66E. doi: 10.1016/j.amjcard.2005.06.007. Am J Cardiol. 2005. PMID: 16098846 Review.
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Grundy SM, et al. J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001. J Am Coll Cardiol. 2004. PMID: 15358046 Review.